 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
98 News |  |
| «12 |
- | simvastatin / Generic mfg.
Journal: Effects of simvastatin on nuclear receptors, drug metabolizing enzymes and transporters expression in Human Umbilical Vein Endothelial Cells. (Pubmed Central) - Apr 12, 2020
This study revealed functional expression of AhR and Nrf2 in HUVECs. Moreover, it was defined that simvastatin induced AhR and its related genes.
- | oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Preclinical, Journal: Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention. (Pubmed Central) - Mar 2, 2020
Improvement of vascular function was confirmed in HPRA and HCC from ED patients and mimicked by another Nrf2 activator, oltipraz...Nrf2 short-term pharmacological activation attenuates age-related impairment of endothelium-dependent and reactive oxygen species (ROS)-induced vasodilation in different rat and human vascular territories by upregulation of Nrf2-related signaling and decreased oxidative stress. In ED patients target tissues, Nrf2 potentiates the functional effect of ED conventional pharmacological therapy suggesting potential therapeutic implication.
- | oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Preclinical, Journal: Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. (Pubmed Central) - Jan 17, 2020
OPZ administration may provide experimental evidence for the possible effect of OPZ on isoproterenol-induced heart failure in rats. Moreover, OPZ administration may have potential utility for the treatment of heart failure.
- |||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Enrollment open: Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Dec 1, 2019
P3, N=144, Recruiting, Sponsor: PharmaKing
Moreover, OPZ administration may have potential utility for the treatment of heart failure. Not yet recruiting --> Recruiting
- |||||||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
New P3 trial: Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Nov 3, 2019
P3, N=144, Not yet recruiting, Sponsor: PharmaKing
- | oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Journal: Mechanism of Calculus Bovis Sativus in inhibiting hepatocyte lipid deposition based on serum pharmacology (Pubmed Central) - Oct 24, 2019
05). All of the above effects could be reversed by oltipraz.In conclusion,CBS-containing serum can significantly inhibit the fructose-induced LO2 liver fat deposition,and the mechanism may be related to reducing intracellular ROS level through the Nrf2 pathway and improving intracellular peroxidation state to reduce apoptosis.
- oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Deficiency Attenuates Hyperglycemia, Hypertension, and Nephropathy via Downregulation of Sodium-Glucose Co-Transporter 2 Expression in db/db Mice (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2706;
In vitro, the effect of oltipraz (Olz, an Nrf2 activator) and overexpression of NRF2 cDNA on SGLT2 expression and SGLT2 promoter activity in human RPTC (HK-2) were assessed...These results identify a novel mechanism by which Nrf2 mediates hyperglycemia-stimulation of Sglt2 expression in diabetes. Funding Government Support - Non-U.S.
- | oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Journal: A Drosophila model of cigarette smoke induced COPD identifies Nrf2 signaling as an expedient target for intervention. (Pubmed Central) - Oct 8, 2019
A pharmacological intervention study performed with oltipraz, an activator of Nrf2 signaling, increased survival of cigarette smoke exposed animals significantly. Thus, the Drosophila COPD model recapitulates many major hallmarks of COPD and it is highly useful to evaluate the potential of alternative therapeutic strategies.
- | oltipraz (PMK-N01GI1) / Canopus Biopharma, Pharmaking
Preclinical, Journal: Analgesic and Antidepressant Effects of Oltipraz on Neuropathic Pain in Mice by Modulating Microglial Activation. (Pubmed Central) - Jun 27, 2019
The inhibition of microglial activation and induction of the Nrf2/HO-1/NQO1 signaling pathway in the hippocampus and/or prefrontal cortex may explain the antidepressant effects of oltipraz during neuropathic pain. These data demonstrate the analgesic and antidepressant effects of oltipraz and reveal its protective and antioxidant properties during chronic pain.
- ||||||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Trial completion, Trial primary completion date: Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Mar 30, 2016
P3, N=283, Completed, Sponsor: PharmaKing
These data demonstrate the analgesic and antidepressant effects of oltipraz and reveal its protective and antioxidant properties during chronic pain. Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Feb 2016
- ||||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Enrollment closed, Trial primary completion date: Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Apr 29, 2015
P3, N=276, Active, not recruiting, Sponsor: PharmaKing
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2015
- |||||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Enrollment open: Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Jul 16, 2014
P3, N=276, Recruiting, Sponsor: PharmaKing
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2015 Not yet recruiting --> Recruiting
- | oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Trial completion: Oltipraz in the Prevention of Lung Cancer in People Who Smoke (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
New P3 trial: Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis (clinicaltrials.gov) - Feb 19, 2014
P3, N=276, Not yet recruiting, Sponsor: PharmaKing
- |||| oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
Trial completion: Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 7, 2013
P2, N=60, Completed, Sponsor: PharmaKing
Active, not recruiting --> Completed Recruiting --> Completed